| Literature DB >> 35514853 |
Jaspreet K Aulakh1, Tarlok S Lobana1, Henna Sood2, Daljit S Arora2, Raminderjit Kaur3, Jatinder Singh3, Isabel Garcia-Santos4, Manpreet Kaur5, Jerry P Jasinski5.
Abstract
The basic aim of this study pertains to the synthesis of silver nitrate complexes and the study of their antimicrobial and anticancer bio-activity. A series of new silver(i) derivatives of N-substituted-imidazolidine-2-thiones (L-NR, R = Et, Pr n , Bu n , Ph), purine-6-thione (purSH2), 2-thiouracil (tucH2), pyrimidine-2-thione (pymSH) and pyridine-2-thione (pySH) of composition [Ag(S-L-NR)(PPh3)2(ONO2)] {R = Et (1), Pr n (2), Bu n (3), Ph (4)}, [Ag2(N,S-purSH2)2(μ-dppm)2](NO3)2·2H2O (5) (dppm = Ph2P-CH2-PPh2), [Ag(L)(PPh3)2](NO3) {L = N,S-purSH2 (6); S-tucH2 (7)}, [Ag(N,S-pymS)(PPh3)2](CH3OH) (8), and [Ag(N,S-pyS)(PPh3)2] (9) have been synthesized and structurally characterized. These new and some previously reported complexes {[Ag2(L-NH)4(PPh3)2](NO3)2 (10), [Ag(L-NMe)2(PPh3)](NO3) (11), and [Ag(S-bzimSH)2(PPh3)2](OAc) (12), L-NH = 1,3-imidazolidine-2-thione; L-NMe = 1-methyl-3-imidazolidine-2-thione and bzimSH2 = benzimidazoline-2-thione)} have shown moderate to high anti-microbial activity against Gram positive bacteria, namely methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (MTCC 740), and Gram negative bacteria, namely Staphylococcus epidermidis (MTCC 435), Enterococcus faecalis (MTCC 439), Shigella flexneri (MTCC 1457) and a yeast Candida albicans (MTCC 22). These complexes have also been found to be bio-safe as studied using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay. The anti-tumor study of silver complexes against human osteosarcoma cell line (MG63) has shown IC50 values in the range of 6-33 μM. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35514853 PMCID: PMC9066168 DOI: 10.1039/c9ra01804b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Chart 1Thio-ligands used in the present investigation.
Chart 2The structures of complexes, 1–9.
IR spectral bands of complexes and free ligandsa,b,c
| Complex/free thio-ligand |
|
| Band I | Band II | Band III | Band IV | NO3− bands |
|---|---|---|---|---|---|---|---|
| [Ag(S-L-NEt)(PPh3)2](NO3) 1 | 3238 m | 1093 s | 1507 s | 1277 s | 1027 m | 747 w |
|
| 3175 m |
| ||||||
|
| |||||||
| Ag(S-L-NPr | 3051 m | 1094 s | 1509 m | 1281 w | 1027 m | 745 s |
|
|
| |||||||
|
| |||||||
| Ag(S-L-NBu | 3183 m | 1095 m | 1518 s | 1285 s | 1029 w | 747 s |
|
|
| |||||||
|
| |||||||
| [Ag(S-L-NPh)(PPh3)2](NO3) 4 | 3128 m | 1094 s | 1519 s | 1244 s | 1027 m | 743 s |
|
|
| |||||||
|
| |||||||
| [Ag2(N,S-purSH2)2(μ-dppm)2]-(NO3)25 | 3259 m | 1095 m | 1507 m | 1282 m | 1027 w | 748 m |
|
|
| |||||||
|
| |||||||
| [Ag(N,S-purSH2)(PPh3)2](NO3) 6 | 3133 w | 1094 m | 1479 m | 1288 s | 1026 w | 743 m |
|
|
| |||||||
|
| |||||||
| [Ag(S-tucH2)(PPh3)2](NO3) 7 | 3139 m | 1092 s | 1565 s | 1239 m | 1001 w | 723 w |
|
|
| |||||||
|
| |||||||
| [Ag(N,S-pymS)(PPh3)2] 8 | — | 1092 m | 1435 s | 1270 w | 1027 w | 744 s | — |
| [Ag(N,S-pyS)(PPh3)2] 9 | — | 1094 m | 1480 m | 1256 w | 1027 w | 723 w | — |
| L-NEt | 3240 m, | ||||||
| 3191 s | — | 1513 s | 1279 m | 1037 m | 792 m | — | |
| L-NPr | 3207 s | — | 1514 s | 1280 s | 1037 w | 806 w | — |
| L-NBu | 3196 s | — | 1514 s | 1284 s | 1041 w | 803 w | — |
| L-NPh | 3203 s | — | 1518 s | 1288 m | 1040 m | 757 s | — |
| purSH2 | 3096 m | — | 1529 m | 1275 m | 1014 m | 782 w | — |
| tucH2 | 3135 m | — | 1567 s | 1240 m | 1004 w | 761 w | — |
| pymSH | 3186 w | — | 1472 w | 1275 s | 1014 s | 783 m | — |
| pySH | 3162 s | — | 1494 m | 1255 m | 1023 w | 743 s | — |
| PPh3 | — | 1088 s | — | — | — | — | — |
| dppm | — | 1096 m | — | — | — | — | — |
See ESI for detailed spectral bands. s = strong, m = medium, w = weak.
Band I has contributions from δN–H + δC–H + νCN; Band II has contributions from νC–N + δN–H + δC–H + νCS; band III has contributions from νC–N + νC–S and band IV has contributions from νC–S.
ν 1 mode of nitrate could not be assigned owing to the bands of thio-ligand and PPh3 ligand in this region.
1H NMR spectral data (δ in ppm) of complexes 1–9 and free ligandsa
| Complex/free thio-ligand | –NH protons | Ring protons of thio-ligand and co-ligands (PPh3/dppm) |
|---|---|---|
| [Ag(S-L-NEt)(PPh3)2(O–NO2)] | 9.25 (s, 1H, NH) | 3.72(m, 4H, C4H2/C5H2); 3.59 (q, 2H, N–CH2); 1.21 (t, 3H, CH3); 7.51 (m, 12H, o-H), 7.40 (m, 18H, m-H, p-H, PPh3) |
| [Ag(S-L-NPr | 7.87 (s, 1H, NH) | 3.48 (t, 2H, C4H2); 3.39 (t, 2H, N–CH2,); 3.29 (t; 2H, C5H2); 1.51 (m; 2H, CH2); 0.85 (t; 3H, CH3); 7.32 (m, 12H, o-H), 7.23 (m, 18 H, m-H, p-H, PPh3) |
| [Ag(S-L-NBu | 8.40 (s; 1H, N3H) | 3.62(dt; 2H, C4H2) |
| [Ag(S-L-NPh)(PPh3)2](NO3) | 9.40 (s, 1H, NH) | 4.18 (t, 2H, C4H2);3.86 (t, 2H, C5H2), 7.36 (m, 21H, o-H, p-H, PPh3+ L-NPh) |
| [Ag2(N,S-purSH2)2(μ-dppm)2] (NO3) | 13.78 (s, 2H, N1,9H) | 8.29 (s, 1H, C8H); 7.73 (s, 1H, C2H); 3.79 (s, 2H, P–CH2–P, dppm), 7.36 (d, 8 H, o-H), 7.20 (t, 4H, p-H), 7.06 (t, 8H, m-H, dppm) |
| [Ag(N,S-purSH2)(PPh3)2](NO3) | 13.78 (s, 2H, N1,9H) | 8.40 (s, 1H, C8H); 8.33 (s, 1H, C2H); 7.41(m, 12H, o-H), 7.27 (m, 18 H, m-H, p-H, PPh3) |
| [Ag(S-tucH2)(PPh3)2](NO3) | 8.28 (s; 2H, N1,3H) | 7.13 (d; 1H, C6H); 5.55 (d; 1H, C5H); 7.37 (m, 12H, o-H), 7.25 (m, 18H, m-H, p-H, PPh3) |
| [Ag(N,S-pymS)(PPh3)2] | — | 7.85 (d; 2H, C4,6H); 6.50 (t; 1H, C5H); 7.34 (m, 12H, o-H), 7.24 (m, 18 H, m-H, p-H, PPh3) |
| [Ag(N,S-pyS)(PPh3)2] | — | 7.39 (t, 1H, C3H); 7.24 (m, 1H, C4H); 6.81 (t, 1H, C5H); 7.57 (m, 13H, C6H +o-H, PPh3); 7.51 (m, 18H, m-H, p-H, PPh3) |
| L-NEt | 6.39 (s, 1H, NH) | 3.59(m, 6H, C4H2/C5H2/N–CH2) |
| L-NPr | 5.91 (s, 1H, NH) | 3.71 (t, 2H, C4H2); 3.58 (m, 2H, N–CH2,); 3.46 (t, 2H, C5H2); 1.65 (m, 2H, CH2); 0.97 (t, 3H, CH3) |
| L-NBu | 6.02 (s, 1H, NH) | 3.64(m, 2H, C4H2) |
| L-NPh | 6.38 (s, 1H, NH) | 4.20 (t, 2H, C4H2); 3.76 (t, 2H, C5H2); 7.60 (m, 2H, o-H),7.42 (m, 2H, m-H), 7.27 (m, H, p-H) |
| purSH2 | 13.70 (s, 2H, N1,9H) | 8.33 (s, 1H, C8H); 8.14 (s, 1H, C2H) |
| tucH2 | 12.37 (s; 2H, N1,3H) | 7.36 (d; 1H, C6H); 5.78 (d; 1H, C5H) |
| pymSH | 8.23 (s; 1H, N1H) | 8.65 (d; 1H, C4H); 7.32 (m; 1H, C6H); 6.79 (t; 1H, C5H) |
| pySH | 13.46 (s; 1H, N1H) | 7.6 (sb, 1H, C6H); 7.35 (t; 1H, C3H); 7.25 (t; 1H, C4H); |
| 6.69 (t; 1H, C5H) | ||
| PPh3 | — | 7.32 (m; o-H, m-H,p-H; 15H) |
| dppm | — | 2.18 (s; 2H, P–CH2–P); 7.44 (m, 8H, o-H), 7.30 (m, 12H, m-H, p-H) |
See ESI for spectra.
(N–CH2) and (ring proton C4H2 or C5H2) got merged.
CDCl3.
DMSO.
N-Ph protons obscured by phenyl ring of PPh3.
The 13C NMR spectral data (δ in ppm) of complexes 1, 3, 5–8 and free ligandsa
| Complex/free ligand | Carbons of thio-ligands | Carbons of co-ligands (PPh3/dppm) | |
|---|---|---|---|
| C2/C6 | Other ring/chain carbons | i-C, o-C, m-C, p-C | |
| [Ag(S-L-NEt)(PPh3)2(O–NO2)]1 | 179.9 | 48.26 (C5), 42.06 (N–CH2), 41.06(C4), 12.23 (CH3) | 133.91 (i-C, |
| [Ag(S-L-NBu | 180.4 | 48.80 (C5), 46.72 (N–CH2), 41.89 (C4), 29.24 (CH2), 19.88 (CH2), 13.78 (CH3) | 133.87 (i-C, |
| [Ag2(N,S-purSH2)2(μ-dppm)2](NO3)25 | 171.6 | 145.91(C2), 133.34 (C4/C8), 128.75(C5) | 131.89 (i-C), 131.31 (o-C, J13C–P = 174 Hz), 128.93 (p-C), 128.74 (m-C, |
| [Ag(N,S-purSH2)(PPh3)2](NO3) 6 | 163.6 | 152.75(C2), 133.63 (C4/C8), 129.25(C5) | 132.60 (i-C, |
| [Ag(S-tucH2)(PPh3)2](NO3) 7 | 163.6 | 164.92(C4), 133.64 (C6), 100.76(C5) | 132.60 (i-C, |
| [Ag(N,S-pymS)(PPh3)2] 8 | 183.2 | 156.16(C4H/C6H), 114.16 (C5H) | 134.29 (i-C, |
| L-NEt | 182.9 | 47.97 (C5), 41.67 (N–CH2), 41.39 (C4), 12.21 (CH3) | PPh3 |
| L-NBu | 183.4 | 48.61 (C5), 46.77 (N–CH2), 41.44 (C4), 29.26 (CH2), 19.99 | |
| (CH2), 13.89 (CH3) | dppm | ||
| 28.12 (CH2) | |||
| purSH2 | 171.4 | 152.08 (C2), 145.04 (C4/C8), 128.76 (C5) | — |
| tucH2 | 161.5 | 176.17 (C4), 142.63 (C6), 106.80 (C5) | — |
| pymSH | 181.9 | 154.69 (C6), 159.08 (C4), 110.01 (C5H) | — |
See ESI for spectra.
CDCl3.
DMSO.
Fig. 1Molecular structure of complex [Ag(S-L-NPr)(PPh3)2(ONO2)] 2.
Fig. 2Molecular structure of complex [Ag(S-L-NBu)(PPh3)2(ONO2)] 3.
Fig. 3Molecular structure of complex [Ag(N,S-purSH2)(PPh3)2](NO3) 6.
Fig. 4Molecular structure of dinuclear complex [Ag2(N,S-purSH2)2(μ-P,P-dppm)2]-(NO3)25.
Fig. 5Molecular structure of complex [Ag(S-tucH2)(PPh3)2](NO3) 7.
Fig. 6Molecular structure of complex [Ag(N,S-pymS)(PPh3)2]·CH3OH 8.
Chart 3Common species found in mass-spectra of complexes.
Antimicrobial activity of complexes 1–12a,b,c
| Complex/free thio-ligand/standard drug | MRSA |
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
|
| |||||||
| [Ag(S-L-NEt)(PPh3)2(O–NO2)] 1 | 23 | 22 | 30 | 23 | 19 | 22 | |
| [Ag(S-L-NPr | 24 | 20 | 24 | 30 | 13 | 21 | |
| [Ag(S-L-NBu | 14 | 13 | 15 | 30 | 23 | 14 | |
| [Ag(S-L-NPh)(PPh3)2(O–NO2)] 4 | 22 | 19 | 20 | 19 | 24 | 18 | |
| {[Ag2(L-NH)4(PPh3)2](NO3)210 | 30 | 24 | 21 | 22 | 15 | 26 | |
| [Ag(S-L-NMe)2(PPh3)](NO3) 11 | 25 | 23 | 30 | 34 | 20 | 24 | |
| [Ag(S-bzimSH)2(PPh3)2] (OAc) 12 | 17 | NA | 12 | NA | NA | 13 | |
| L-NH | NA | NA | NA | NA | 15 | NA | |
| L-NMe | NA | NA | 13 | 12 | NA | NA | |
| L-NEt | NA | NA | 13 | 12 | NA | NA | |
| L-NPr | NA | NA | 13 | 12 | NA | NA | |
| L-NBu | 12 | NA | NA | 12 | NA | NA | |
| L-NPh | NA | NA | 13 | 12 | NA | NA | |
| BzimSH | 15 | 15 | NA | NA | 16 | 13 | |
| PPh3 | NA | NA | NA | NA | NA | NA | |
|
| |||||||
| [Ag2(N,S-purSH2)2(μ-dppm)2]-(NO3)2 5 | 13 | 12 | 12 | NA | NA | 17 | |
| [Ag(N,S-purSH2)(PPh3)2]-(NO3) 6 | 15 | 12 | 14 | NA | NA | 18 | |
| [Ag(S-tucH2)(PPh3)2](NO3) 7 | 20 | 14 | 14 | NA | 26 | 20 | |
| [Ag(N,S-pymS)(PPh3)2] 8 | 12 | NA | NA | NA | NA | 13 | |
| [Ag(N,S-pyS)(PPh3)2] 9 | 20 | NA | 14 | 13 | NA | 18 | |
| purSH2 | 18 | 13 | NA | NA | NA | NA | |
| tucH2 | 19 | 16 | NA | NA | NA | 12 | |
| PymSH | 19 | 17 | 17 | NA | 20 | 23 | |
| PySH | 20 | 19 | 18 | NA | 14 | 30 | |
| dppm | NA | NA | NA | NA | NA | NA | |
| Gentamicin | 33 | 26 | 25 | 27 | 34.5 | — | |
| Amphotericin B | — | — | — | — | — | 34 | |
All measurements are in mm diameter of the inhibition zone (N.A. indicates no activity).
The standard deviation varied in the range 0–1 based on three readings.
Studies were made in DMSO.
Commercially available antimicrobial agents.
MRSA.
Staphylococcus aureus.
Staphylococcus epidermidis.
Enterococcus faecalis.
Shigella flexneri.
C. albicans.
Gentamicin acts as positive control against bacteria (MRSA, S. aureus, S. epidermidis, E. faecalis, S. flexneri) and amphotericin B acts as positive control against yeast, C. albicans.
Minimum inhibitory concentration (μg mL−1) of silver(i) complexes 1–12a,b
| Complex/standard drug | MRSA |
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| ||||||
| 1 | 10 | 10 | 5 | 10 | 50 | 50 |
| 2 | 50 | 50 | 10 | 7 | ND | 1010 10 |
| 3 | ND | ND | 1000 | 1 | 7 | ND |
| 4 | 10 | 500 | 50 | 500 | 10 | 750 |
| 10 | 5 | 10 | 50 | 50 | 1000 | 5 |
| 11 | 7 | 10 | 7 | 1 | 50 | 10 |
| 12 | 7 | ND | ND | ND | ND | ND |
|
| ||||||
| 5 | ND | ND | ND | ND | ND | 50 |
| 6 | 1250 | ND | ND | ND | ND | 50 |
| 7 | 50 | ND | ND | ND | 7 | 10 |
| 8 | ND | ND | ND | ND | ND | ND |
| 9 | 50 | ND | ND | ND | ND | 50 |
| Gentamicin | 10 | 0.5 | 30 | 30 | 5 | — |
| Amphotericin B | — | — | — | — | — | 0.1 |
MIC in μg mL−1.
ND-not determined.
OD values of silver complexes (1, 3, 4, 7, 8, 11) at wavelength 590 nm
| Complexes | OD values | Cell viability |
|---|---|---|
| [Ag(L-NEt)(PPh3)2(O–NO2)] 1 | 0.237 | 79.53% |
| [Ag(L-NBu | 0.224 | 75.17% |
| [Ag(L-NPh)(PPh3)2(O–NO2)] 4 | 0.288 | 96.31% |
| [Ag(tucH2)(PPh3)2](NO3) 7 | 0.565 | 84% |
| [Ag(pymS)(PPh3)2] 8 | 0.666 | 99.10% |
| [Ag(L-NMe)2(PPh3)](NO3) 11 | 0.271 | 90.94% |
OD value of control = 0.298.
OD value of control = 0.672.
Fig. 7Effect of concentration of complexes 1–5 on viability of MG 63 cells; untreated cells represent control.
Fig. 8Effect of concentration of complexes 6, 7, 9–11 on viability of MG 63 cancerous cells; where untreated cells represent control.
Fig. 9Plot of IC50 values of complexes 1–6, 7, 9–11 against MG 63 cells.
Anticancer activity of silver complexes (1–7, 9–11) against human bone cancer MG63 cell linea
| Complexes | IC50 (μM) | IC50 (μM) | |
|---|---|---|---|
| [Ag(L-NEt)(PPh3)2(O–NO2)] 1 | 13.20 | [Ag(N,S-purSH2)(PPh3)2](NO3) 6 | 14.58 |
| [Ag(L-NPr | 6.42 | [Ag(S-tucH2)(PPh3)2](NO3) 7 | 16.61 |
| [Ag(L-NBu | 9.21 | [Ag(N,S-pyS)(PPh3)2] 9 | 15.80 |
| [Ag(L-NPh)(PPh3)2(O–NO2)] 4 | 29.22 | [Ag2(L-NH)4(PPh3)2]-(NO3)210 | 8.17 |
| [Ag2(N,S-purSH2)2(μ-dppm)2]-(NO3)25 | 7.62 | [Ag(L-NMe)2(PPh3)](NO3) 11 | 13.33 |
Ligands: L-NR, R = H, Me, Et, Pr. Bu and Ph; PPh3: IC50 (μM) is >100; purSH2, 24.78, tucH2, 44.26 and pySH, 29.66.
| 2 | 3 | 5 | |
|---|---|---|---|
| Empirical formula | C42H42AgN3O3P2S | C43H44AgN3O3P2S | C60H56Ag2N10O8P4S2 |
| CCDC |
|
|
|
|
| 838.65 | 852.68 | 1448.88 |
|
| 293(2) | 173(2) | 293(2) |
|
| Cu-Kα, 1.54178 | Mo-Kα, 0.71073 | Cu-Kα, 1.54178 |
| Crystal system | Triclinic | Monoclinic | Monoclinic |
| Space group |
|
|
|
|
| 10.5641(6) | 13.6628(4) | 25.2895(7) |
|
| 12.9718(7) | 16.2436(5) | 13.2208(2) |
|
| 15.3593(8) | 18.8410(6) | 23.5888(7) |
|
| 77.698(4) | 90 | 90 |
|
| 82.402(4) | 105.902(3) | 125.671(4) |
|
| 79.796(4) | 90 | 90 |
|
| 2014.12(19) | 4021.4(2) | 6407.1(4) |
|
| 2 | 4 | 4 |
|
| 1.383 | 1.408 | 1.502 |
|
| 5.577 | 0.675 | 6.958 |
|
| 864 | 1760 | 2944 |
| Reflns collected | 14 231 | 36 999 | 12 856 |
| Unique reflns | 7658 ( | 13 487 ( | 6067 ( |
| Data/restraints/parameters | 7658/0/480 | 13 487/0/479 | 6067/223/447 |
| Reflecs with [ | 6347 | 9990 | 5309 |
| Final |
|
|
|
| w | w | w | |
| Final |
|
|
|
| w | w | w | |
| Largest diff. peak/hole e Å−3 | 1.720 and −0.671 | 1.193 and −0.482 | 1.160 and −0.441 |
| 6 | 7 | 8 | |
|---|---|---|---|
| Empirical formula | C41H34AgN5O3P2S | C40H36AgN3O5P2S | C41H37AgN2OP2S |
| CCDC |
|
|
|
|
| 846.60 | 840.59 | 775.59 |
|
| 293(2) | 293(2) | 173(2) |
|
| Cu-Kα, 1.54178 | Cu-Kα, 1.54178 | Mo-Kα, 0.71073 |
| Crystal system | Monoclinic | Triclinic | Triclinic |
| Space group |
|
|
|
|
| 9.2210(3) | 12.5062(7) | 10.1240(4) |
|
| 25.4962(8) | 13.1744(7) | 13.4635(6) |
|
| 17.0609(5) | 15.1280(7) | 14.1829(6) |
|
| 90 | 99.534(4) | 77.466(4) |
|
| 100.830(3) | 103.826(5 | 78.784(4) |
|
| 90 | 114.897(5) | 78.993(4) |
|
| 3939.6(2) | 2092.7(2) | 1828.62(14) |
|
| 4 | 2 | 2 |
|
| 1.427 | 1.334 | 1.409 |
|
| 5.728 | 5.408 | 0.730 |
|
| 1728 | 860 | 796 |
| Reflns collected | 16 236 | 15 670 | 21 420 |
| Unique reflns | 7485 ( | 7954( | 12 042 ( |
| Data/restraints/parameters | 7485/0/482 | 7954/0/472 | 12 042/0/436 |
| Reflecs with [ | 6025 | 6920 | 9569 |
| Final |
|
|
|
| w | w | w | |
| Final |
|
|
|
| w | w | w | |
| Largest diff. peak/hole e Å−3 | 1.114 and −0.612 | 0.745 and −0.972 | 0.808 and −0.488 |
| Mononuclear complexes | |||||||
|---|---|---|---|---|---|---|---|
| 2 | 3 | 6 | 8 | 7 | |||
| Ag–S | 2.6161(13) | 2.5340(7) | Ag–S | 2.6478(10) | 2.5502(6) | Ag–S | 2.5464(9) |
| Ag–O | 2.496(4) | 2.4999(19) | Ag–N | 2.468(4) | 2.579(2) | Ag–P | 2.4531(7) |
| Ag–P | 2.4552(11) | 2.4524(6) | Ag–P | 2.4511(8) | 2.4477(6) | Ag–P | 2.4787(8) |
| Ag–P | 2.4450(11) | 2.4554(6) | Ag–P | 2.4301(9) | 2.4528(6) | S–C | 1.688(3) |
| S–C | 1.695(6) | 1.708(3) | S–C | 1.693(4) | 1.722(3) | O1–N | 1.264(5) |
| O1–N | 1.175(7) | 1.232(3) | O1–N | 1.200(6) | — | O2–N | 1.227(5) |
| O2–N | 1.284(7) | 1.249(3) | O2–N | 1.218(6) | — | O3–N | 1.235(6) |
| O3–N | 1.227(7) | 1.233(3) | O3–N | 1.240(5) | — | — | |
| O–N–O | 117.9(5), 121.8(5), 120.1(5) | ||||||
| P–Ag–S | 109.64(4) | 114.81(2) | P–Ag–S | 101.23(3) | 115.58(2) | P–Ag–S | 119.40(3) |
| P–Ag–S | 108.08(4) | 108.88(2) | P–Ag–S | 120.37(3) | 118.61(2) | P–Ag–S | 110.51(3) |
| P–Ag–O1 | 98.00(12) | 101.72(5) | P–Ag–N | 108.14(10) | 105.16(5) | P–Ag–P | 124.53(2 |
| P–Ag–O1 | 109.00(12) | 102.46(2) | P–Ag–N | 105.28(9) | 106.64(5) | O–N–O | 119.5(4) |
| O1–Ag–S | 97.59(13) | 103.09(6) | N–Ag–S | 79.87(9) | 61.89(5) | O–N–O | 121.7(5) |
| P–Ag–P | 129.48(4) | 122.73(2) | P–Ag–P | 130.17(3) | 125.17(2) | O–N–O | 118.8(4) |
| Dinuclear complex 5 | |||||||
|---|---|---|---|---|---|---|---|
| Ag–S | 2.7239(9) | S–C; Ag⋯Ag | 1.685(3) 3.466 (4) | P–Ag–S | 124.79(3) | P–Ag–N | 94.06(6) |
| Ag–P | 2.4273(6) | O1–N | 1.242(6) | P– Ag–S1 | 91.39(2) | S– Ag–N | 77.27(7) |
| Ag–P | 2.4677(7) | O2–N | 1.224(7) | P– Ag–N | 97.98(6) | P– Ag–P | 143.54(2) |
| Ag–N | 2.553(3) | O3–N | 1.264(6) | O–N–O | 122.1(6) | 120.7(5) | 117.1(6) |